News | November 25, 2023
Laurus Labs acquires 87.59% stake in Laurus Bio Private
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
The Product will be manufactured at the company's facility in Bengaluru
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Distributes Ayushman cards to several beneficiaries
Subscribe To Our Newsletter & Stay Updated
